Life Sciences

Alexion appoints Deborah Dunsire, M.D. to Board

January 23, 2018

Alexion Pharmaceuticals, Inc. today announced that Deborah Dunsire, M.D. has been appointed to the Company’s Board of Directors as a new independent director. Dr. Dunsire is a proven leader in the biopharmaceutical industry with three decades of experience and a successful track record of growing..

Fed up with drug companies, hospitals decide to start their own

January 22, 2018

For years, hospital executives have expressed frustration when essential drugs like heart medicines have become scarce, or when prices have skyrocketed because investors manipulated the market. Now, some of the country’s largest hospital systems are taking an aggressive step to combat the problem: They plan..

AbbVie adding 100 jobs as part of $139M oncology expansion in Ireland

January 22, 2018

CEO Richard Gonzalez has made it clear he expects new oncology drugs to fill the yawning revenue gap AbbVie will experience with the loss of Humira patent protection. The company is prepping for that day with a $139 million expansion at a plant in Ireland..

Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion

January 22, 2018

French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, in a deal which it said would boost earnings and strengthen its presence in treatments for rare diseases. The move comes at a time of renewed interest by large drugmakers..

Heptares, Sosei shuffle leadership as CSO Marshall departs

January 22, 2018

Fiona Marshall, Ph.D., is set to leave Sosei. Marshall has served as CSO of the company since it bought Heptares but is now departing to take on a senior role at another business. Sosei responded to the resignation of Marshall—who will leave at the end..

Inositec names ex-Roche, Novartis staffer as CMO

January 19, 2018

Inositec has named former Roche and Novartis staffer Frits van Alphen, M.D., as its CMO. Van Alphen joins Inositec as the biotech gears up to move its lead vascular calcification candidate into the clinic next year. Zurich, Switzerland-based Inositec hired van Alphen away from Roche,..

Largest Ablynx investor would consider improved Novo Nordisk bid

January 19, 2018

The largest shareholder in Belgian biotech group Ablynx regards the 2.6 billion euro ($3.2 billion) offer made by Denmark’s Novo Nordisk as too low but would be willing to consider a higher figure. Van Herk Investments, which owns about 10.2 percent of Ablynx, said it..

U.K.-based Almac snags EU site in preparation for Brexit ‘uncertainty’

January 19, 2018

While Big Pharma companies have equivocated about whether to pull drug production from the U.K. because of Brexit, CDMO Almac quickly went out and did something about it. It obtained a site in the EU and is now investing about $30 million on upgrades. Based..

J&J attracts Chinese interest for diabetes business in potential $3B to $4B deal: Sources

January 18, 2018

Chinese bidders are circling a diabetes care business owned by the world’s largest health-care company Johnson & Johnson in a deal that could fetch up to $4 billion, five people with direct knowledge told Reuters. New Brunswick, N.J.-based J&J said in January last year it..

Forma’s John Hohneker takes the reins at Anokion

January 18, 2018

After shepherding Forma Therapeutics from its discovery stage to clinical trials as its R&D chief, John Hohneker is joining Anokion Therapeutics as president and CEO, effective Jan. 22. “John brings tremendous experience in biologics development to Anokion, including in the immunology space. His broad leadership..